Table 4.
CAR-T therapy for metastatic colorectal cancer in preclinical or clinical trials
| Intervention | Stage of research | Trial ID | Design (N) | Subject |
|---|---|---|---|---|
| Anti-CEA CAR-T cells | Clinical trial | NCT02349724 | Phase I (N = 10) | Relapsed and refractory mCRC |
| Human GUCY2C-targeted murine CAR-T cells | Preclinical trial | - | - | - |
| CYAD-01 | Clinical trial | NCT03310008 | Phase I (N = 36) | CRLM |
| CYAD-101 | Clinical trial | NCT03692429 | Phase I (N = 49) | Unresectable mCRC |
| CYAD-101 + pembrolizumab | Clinical trial | NCT04991948 | Phase I (N = 34) | Unresectable mCRC |
mCRC metastatic colorectal cancer